Afstyla
lonoctocog alfa · CSL Behring GmbH
AUTHORISED IN THE EUWhat Afstyla is used for
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Afstyla can be used for all age groups.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Afstyla
- Active substance
- lonoctocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- CSL Behring GmbH
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Afstyla used for?
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Afstyla can be used for all age groups.
What is the active substance in Afstyla?
Afstyla contains lonoctocog alfa.
Who makes Afstyla?
The EU marketing authorisation holder is CSL Behring GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU